BioAge brings in $90M for age-related disease treatment
December 4, 2020- Share:
BioAge has raised a $90 million Series C co-led by Andreessen Horowitz and angel investor Elad Gil. The Richmond, Calif.-based biotech company is a developer of therapeutics that target aging and age-related health problems such as Alzheimer's and cardiovascular disease. Founded in 2015, the startup plans to use the funding to advance clinical trials of two therapies in 2021. BioAge raised $23 million at an $85 million valuation in January 2019.
Additional Investors
- Share:
-
-
-
-